For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or "species" of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.
Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.
Scope of the Report:
This report focuses on the Acinetobacter Infections Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
In the last several years, global market of Acinetobacter Infections Treatment developed rapidly, with an average growth rate of 2.96%. In 2016, United States Market Size of Acinetobacter Infections Treatment is nearly 22 M USD. For developing product, there are 1 in Phase III, 1 in Phase ?, 4 in Phase 1 and 8 in Preclinical. The total investment for Acinetobacter Infections Treatmen Drugs developing is around 90 M USD.
The global average Cost of Acinetobacter Infections Treatment is in the decreasing trend, from 2901 USD/Case in 2012 to2870 USD/Case in 2016. With the situation of global economy, prices will be in decreasing trend in the following five years.
The classification of Acinetobacter Infections Treatment includes Sulbactam, Carbapenems , Aminoglycosides, Polymyxins, Tigecycline and Others Treatment, and the proportion of Aminoglycosides in 2016 is about 18%, and the proportion is in decreasing trend from 2012 to 2016.
The worldwide market for Acinetobacter Infections Treatment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Entasis Therapeutics
- Adenium Biotech
- Hsiri Therapeutics
- Aridis Pharmaceuticals
- LegoChem Biosciences
- Atterx Biotherapeutics
- Sealife PHARMA
- Tetraphase Pharmaceuticals
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
There are 15 Chapters to deeply display the global Acinetobacter Infections Treatment market.
Chapter 1, to describe Acinetobacter Infections Treatment Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Acinetobacter Infections Treatment, with sales, revenue, and price of Acinetobacter Infections Treatment, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Acinetobacter Infections Treatment, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Acinetobacter Infections Treatment market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Acinetobacter Infections Treatment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source